8-K - ENDV - Equibles

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES

EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 28, 2023

ENDONOVO

THERAPEUTICS, INC.

(Exactname of registrant as specified in its charter)

Delaware	000-55453	45-2552528
(State<br> or other jurisdiction <br><br> of incorporation)	(Commission<br><br> File Number)	(IRS<br> Employer<br><br> Identification No.)

6320Canoga Avenue**, 15^th^Floor**

WoodlandHills, CA 91367

(Address of principal executive office)(Zip Code)

Registrant’s telephone number, including area code: (800) 489-4774

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement<br> communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title<br> of each class	Trading<br> Symbol(s)	Name<br> of each exchange on which registered
None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item1.01 Entry into a Material Definitive Agreement.

On March 28, 2023, Endonovo Therapeutics, Inc. (“we”, “us” or the “Company”) entered into a binding letter of intent (the “LOI”) with PEMF Holdings, LLC, a Delaware limited liability company controlled by Ira Weisberg, who is presently a consultant to the Company operating its medical device operations, relating to the spin-off of our subsidiary, SofPulse, Inc. (the “Spin-Off”) While the parties intend to enter into a more formal agreement, they have agreed that the purchase price is expected to be from $50,000,000 to $100,000,000 and equal to the value of SofPulse, Inc.’s assets as determined by a valuation thereof by Ocean Tomo. At the time of the completion of the Spin-Off, SofPulse, Inc. will own all necessary intellectual property for the medical application of our PEMF technology and all related assets including inventories while we will retain rights to the human non-medical and telehealth markets. Until the completion of the Spin-Off, which will require, among other things, the entry into a formal detailed agreement containing full sets of representations and warranties typical of agreements of this type and the filing with the Securities and Exchange Commission and effectiveness of a Registration Statement on Form S-1, Alan Collier, our CEO will own super voting preferred stock in SofPulse, Inc. which will give him voting control of the company and Collier will release these shares upon completion of the purchase. We anticipate that the completion of the Spin-Off will take approximately six months, although no assurance can be given as to any particular time frame.

The foregoing is only a summary of the terms of the APA which is included as an exhibit to this report.

Item9.01 Financial Statements and Exhibits.

(a)	Financial<br> Statements

None

(b) Exhibits

10.1	Binding Letter of Intent between the Company and PEMF Holdings, LLC, dated March 28, 2023.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 29, 2023

ENDONOVO THERAPEUTICS, INC.
By:	/s/ Alan Collier
	Alan<br> Collier
	Chief<br> Executive Officer

Exhibit10.1

PEMFHOLDINGS, LLC

2302Harpers Crossing

Langhorne,PA 19047

March 23, 2023

Alan Collier, CEO

Endonovo Therapeutics, Inc.

6320 Canoga Avenue, 15^th^ Floor

Woodland Hills, CA 91367

Subject:Purchase of SofPulse, Inc.

Dear Mr. Collier:

This Letter of Intent (“LOI”) is a firm commitment to purchase all the common shares of stock of SofPulse, Inc. (the “Company”), a Delaware corporation and a wholly owned subsidiary of Endonovo Therapeutics, Inc., a Delaware corporation (“ENDV”). Based on these agreed to terms the purchase the shares of the Company shall be completed with completion of and full execution of a Definitive Purchase Agreement. This document outlines the commitment by PEMF HOLDINGS, LLC., a Delaware limited liability company (“Buyer”) with respect to the purchase (“Transaction”) of all of the shares of the Company from ENDV which is also sometimes referred to as the “Seller” on the following terms:

1.Structure of Transaction.

The Buyer or its affiliated entity set up for the Transaction shall acquire all of the shares of the Company which at the time of the Closing will have, in general terms, the assets set forth herein including, but not limited to all, accounts receivable, inventory , machinery, equipment, cash, cash equivalents, loss carry forwards, marketable securities, engineering data, databases, systems, designs, computer hardware and software, records, work in process, contracts, contract backlog, intellectual property and know-how, company name, all brand names, operating and equipment leases, licenses, leasehold improvements, permits, franchises, Intellectual Property (such as, but not limited to patents, as listed in Exhibit A, and licensing agreements and all other intangible and all tangible property (except for real estate assets and profits (cash) not distributed etc.) (the “Business”). The list of assets provided in Exhibit A will be confirmed and, if necessary, be updated in the Definitive Agreement. The acquired Pulsed Electromagnetic Field (PEMF) technology is defined in Exhibit B.

| Page 1 of 11 |

| --- | | a. | Buyer shall not assume any liabilities of Seller except those expressly set forth in the following sections 1.a.i through 1.a.vi. The following liabilities of the Seller shall be assumed by the Buyer | | --- | --- | | i. | Buyer shall assume those contracts with independent third parties (which Seller hereby represents and warrants are transferable) and customer/client contracts that were incurred in the ordinary course of business for goods and services (excluding professional, banking and other such services) required to conduct the business of the Company consistent with its historical practice. This is inclusive of the material agreements that provide reoccurring revenue to Seller) prior to Closing. | | --- | --- | | ii. | Buyer shall assume or make comparable arrangements with respect to employee payroll and benefit obligations, except for Seller’s personal employee related obligations. | | iii. | Acceptance of all employees offered by Buyer of new employment agreements and terms. | | iv. | Buyer shall assume the trade accounts payables of the Seller. | | v. | Buyer shall assume only contingent customer liabilities known at the time of Closing including liabilities and refunds and provided in writing by the Seller | | vi. | Prior to the Closing, Buyer shall be responsible for complying with any regulation, order or request from any state or federal government agency as well as the liability for the payment of refunds, fines or penalties imposed by these agencies for a period of twelve (12) months from the date of Closing for any acts of non-compliance performed prior to the Closing |

The foregoing assumption of warranty, contract, employee obligations, and trade accounts payable contingent liabilities, state mandated requests or orders is expressly subject to results of Buyer’s due diligence with respect thereto. If, during due diligence, significant potential liability of Seller is discovered by Buyer, the parties agree to negotiate an appropriate amount of the purchase price (“Holdback Amount”) sufficient to protect the Buyer to be held in escrow for a period to be determined through due diligence.

All other liabilities of the Seller (contingent or otherwise) shall remain obligations of Seller.

2.Purchase Price. The agreed upon n purchase price for all the assets, described above is the valuation amount in US dollars in provided in the Fairness Valuation Report being developed by Ocean Tomo (expected range should between $50 and $100 million dollars) the senior notes with Eagle Equities (the “Senior Notes”), if they haven’t paid prior to Closing.

3.Payment of Purchase Price. The Purchase Price shall include:

i.	CASH:<br> Paid in United States funds via wire transfer at the Closing or in marketable securities of SofPulse, Inc., after SofPulse. Inc is<br> NASDAQ listed or similar listed exchange, less any Holdback Amount negotiated between the parties as a result of the discovery of<br> any potential Seller liability per section 1 of this Agreement along with the “Senior notes” which will be assigned the<br> Buyer if not already redeemed prior
ii.	Holdback<br> Amount, if applicable, will be payable at the earlier of either a) the conclusion of the negotiated term of such amount, or b) the<br> satisfaction or elimination of the related liability for which the Holdback Amount was withheld.

| Page 2 of 11 |

| --- |

5.Non-Compete Agreements. As a condition to the Closing of the Transaction, Sellers shall enter into usual and customary five (5) year non-compete agreements covering the United States and any other jurisdiction that Buyer finds during its due diligence that Seller either operates in or may operate in the future with respect to the Business.

6.Keymen and Other Arrangements.

A condition to the Closing of the Transaction is Buyer’s ability to enter into a one-year management consulting contract to provide transitionary services with Alan Collier providing for compensation of no less than $240,000. In addition, Collier shall have super voting preferred shares that allow him to control 51% of the vote in all matters voted on by shareholders which shares that will be canceled at the payment of the purchase price as delineated in Section 3. Such preferred shares shall remain outstanding until the cash portion of the purchase price has been delivered to ENDV and the securities issued by Buyer may be distributed to ENDV shareholders as marketable securities suitable for deposit at a securities broker and sale by them in market transactions.

Additionally, Buyer will identify certain current employees of the Business to be designated by the Buyer as “key” for similar positions on similar terms of employment and/or assume current agreements.

Buyer and Seller shall agree on timing and content of disclosure of the Transaction to employees of the Company.

7.Further Conditions to Closing. Closing of the Transaction is also subject to the following conditions:

i.	The<br> Assets shall be free and clear of all liens and encumbrances and Buyer shall receive good and marketable title thereto or any lien<br> shall be satisfied at Closing.
ii.	At<br> the Closing date of the Transaction, the financial condition of the Seller, including, but not limited to, assets and liabilities<br> of the Seller, shall be as set forth in the financial statements except for changes arising as a result of the conduct of the Company’s<br> business in its ordinary course since January 18, 2023, and consistent with its historical practices, has not materially changed.<br> Seller shall not give any new or special discounts or pricing on inventory or accounts receivable without prior written consent of<br> Buyer.
iii.	All<br> taxes due and payable by the Company have been fully paid, without regard to any deferral by reason of extension, payment programs,<br> or any other reason, shall have been paid in full;
iv.	There<br> shall have been no material adverse changes (MAC), events or developments affecting the Company or the Seller;
v.	Buyer<br> shall have received financing under terms acceptable to Buyer to complete the Transaction;
vi.	All<br> state, local and other governmental approvals and all other consents or approvals of any third parties inclusive but not limited<br> to existing landlord/leasing arrangements necessary to complete the Transaction shall have been received; and

| Page 3 of 11 |

| --- | | vii. | Seller shall provide usual and customary representations, warranties, covenants and indemnification of obligations (to be defined in the Purchase Agreement). | | --- | --- | | viii. | Seller shall disclose to Buyer any existing, pending or threatened litigation that the Company is or potentially involved in, including but not limited to by customers, vendors, employees and third parties, as well as any existing, pending, or threatened inquiry, investigation or action from any state or federal government authority as any such actions affect the amount of Seller liability (hereinafter referred as “Known Liabilities”). Said disclosure shall include copies of all correspondence, sent and received, whether by letter or electronically, and a status report of each issue. |

8.Due Diligence. The Buyer’s willingness to proceed with this transaction is subject to completion of Due Diligence in form and substance satisfactory to Buyer in its sole and absolute discretion. Due Diligence may continue and be amended or expanded as Buyer sees as necessary through to the date of Closing of the Transaction and results of its confirmatory business, financial and legal due diligence. The Parties agree to cooperate with each other in a prompt and timely fashion in connection with the completion of the due diligence process. Seller shall permit representatives of the Buyer to have full access at all reasonable times, and in a manner so as not to interfere with the normal business operations of Seller, to all customers, suppliers, premises, properties, personnel, books, records, contracts and documents of or pertaining to Seller or the Business. Such representatives shall be permitted to make copies and extracts from such documents.

9.Conduct of Business. During the Due Diligence process and prior to Closing of the Transaction, Seller shall:

i.	Maintain<br> the operations and goodwill of the business and the Seller, shall use its reasonable best efforts to retain the services of present<br> officers and employees and contractors, and continue their relationships with persons having business dealings with Seller;
ii.	Use<br> its reasonable best efforts to maintain all of the Assets in their current condition, ordinary wear and tear excepted, and insurance<br> on all of the Assets in such amounts and of such kinds comparable to that in effect on the date of this letter; and
iii.	maintain<br> the books, accounts and records of Seller consistent with past practices, including recognition of revenues and expenses, continue<br> to collect accounts receivable and pay accounts payable utilizing normal procedures and without discontinuing or accelerating payment<br> of such accounts and comply with all contractual and other obligations applicable to the Seller;
iv.	not,<br> without the Buyer’s consent, which shall not be unreasonably withheld, make any change to, or otherwise amend in any way, the<br> contracts with, salaries, wages or other compensation of, any officer, director, employee, contractor, agent or other similar representative<br> of Seller (including any increase in any benefits or benefit plan costs or any change in any bonus, insurance, pension, compensation<br> or other benefit plan);

| Page 4 of 11 |

| --- | | v. | Not hire any officer, director, employee, agent or other similar representative of Seller except non-management level employees hired in the normal course of business without the consent of the Buyer which consent shall not be unreasonably withheld; | | --- | --- | | vi. | Not incur any indebtedness for borrowed money and not pledge, grant liens or security interests in any of the Assets without the consent of the Buyer which consent shall not be unreasonably withheld; | | vii. | Not sell, transfer or dispose of any Assets except for sales of equipment in the ordinary course of business. |

10.No Solicitation/No Shop. There will be a No Solicitation/No Shop requirement for 180 days past the signing of this agreement. Within said time period Buyer and Seller will act in good faith to negotiate and execute a definitive purchase agreement which shall contain among other items but not limited to the outstanding contingencies outlined in this Letter of Intent. For sake of clarity, A No Solicitation/No Shop requirement is defined as the Seller, nor shall the members, directors, officers, contractors, agents or representatives of the Company encourage, facilitate, solicit, authorize the solicitation of, or enter into any discussion with any third party (including the provision of any information to a third party) concerning any offer or possible offer from any such third party or enter into any agreement or understanding of any kind to purchase, lease, or otherwise acquire all or a substantial portion of the Assets, the business or any capital stock of the Seller until this Transaction is closed or this Agreement is terminated by either party.

PURCHASE AGREEMENT: The Definitive Purchase and Sale Agreement shall be drafted by Buyer’s attorneys.

11.Expenses. The Buyer and Sellers each shall be responsible for the payment of its own expenses and professional fees incurred in connection with the negotiation and consummation for the transaction described herein.

12.Confidentiality. No disclosure of the transaction terms described herein (other than to the advisors and consultants of the Buyer and Sellers) shall be made without the approval of both parties, except as required by law. The Buyer has the right to disclose details of the transaction in a press release. Prior to discloser, the Seller will have the right review and accept discloser, approval will not be unreasonably withheld.

13.Broker Fee. The Buyer and Seller acknowledge that each shall be solely responsible for any broker fees or expenses they incur.

14.Closing Date. Subject to Sellers’ performance of its obligations set forth in this letter and Buyer’s ability to undertake and complete such actions as are necessary to affect the Transactions contemplated by this letter, Buyer estimates to close the funding of the Transaction on or before September 27, 2023 subject to financing and regulatory requirements.

| Page 5 of 11 |

| --- |

15.Miscellaneous.

The Definitive Agreement shall be construed under the laws of the State of California in the venue of the County of Los Angeles as such laws are applied to contracts executed, delivered and to be entirely performed within such jurisdiction. In case of a dispute the prevailing party shall be entitled to all of its reasonable legal fees and costs. All disputes shall be resolved through binding arbitration. The Definitive Agreement contains the entire agreement between the parties and supersedes all prior and contemporaneous agreements, representations and understandings (either oral or written) of the parties. No modification, amendment, supplement or waiver of any of the provisions of this Letter of Intent shall be effective unless in writing specifically referring hereto and executed by both parties.

If the above accurately sets forth your understanding of our mutual intentions, please so indicate by signing a copy of this letter of intent in the space provided below and returning it to the Buyer no later than March 28, 2023

Very<br> truly yours,
[Buyer]<br> PEMF HOLDINGS, LLC
/s/ Ira Weisberg
By:	IRA WEISBERG, SOLE MANAGING MEMBER,
AGREED<br> & ACCEPTED:
this<br> day of March 28, 2023
[Seller]<br> ENDONOVO THERAPEUTICS, INC.
/s/ Alan Coliier
BY:	ALAN COLLIER, CEO

| Page 6 of 11 |

| --- |

EXHIBIT A

List of assets below:

| Page 7 of 11 |

| --- |

| Page 8 of 11 |

| --- |

| Page 9 of 11 |

| --- |

| Page 10 of 11 |

| --- |

EXHIBIT B

DESCRIPTION OF ACQUIRED TECHNOLOGY

Shortwave diathermy medical devices which apply to the body electromagnetic energy at a radio frequency (RF) of 27.12 MHz for the treatment of human medical conditions. The human non-medical shall be retained by Seller at Closing through an exclusive non-royalty bearing license.

| Page 11 of 11 |

| --- |